Coxitis in axial spondyloarthritis: the unmeasured, yet functionally most important, radiographic progression

Rocha, Francisco Airton Castro da; Deodhar, Atul

doi:10.1097/cm9.0000000000001743

Cited by 3 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As hip joint involvement in AS has a serious negative impact on the course of the disease, findings concerning the effect of AS therapy on the progression of coxitis are clinically valuable 2,4 …”

Section: Discussionmentioning

confidence: 99%

“…The hip joint is the most frequently affected non‐axial joint in AS patients 2 . It has been reported that the hip joint is involved in 24%‐54% of AS cases 3–5 .…”

Section: Introductionmentioning

confidence: 99%

“…1 The hip joint is the most frequently affected non-axial joint in AS patients. 2 It has been reported that the hip joint is involved in 24%-54% of AS cases. [3][4][5] Hip joint inflammation (coxitis) dramatically worsens patient mobility and quality of life and is associated with worse Bath Ankylosing Spondylitis Functional Index (BASFI) score and disease outcomes.…”

Section: Introductionmentioning

confidence: 99%

“…[3][4][5] Hip joint inflammation (coxitis) dramatically worsens patient mobility and quality of life and is associated with worse Bath Ankylosing Spondylitis Functional Index (BASFI) score and disease outcomes. 2 Joint inflammation in AS leads to different types of structural damage: inappropriate osteogenesis in the spine and sacroiliac joints and destructive erosive processes in the hip joints. 6 The inflammatory cytokines tumor necrosis factorα (TNFα) and interleukin-17 appear to play an essential role in AS pathogenesis.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Improvement of clinical and radiological manifestations of coxitis in patients with ankylosing spondylitis treated with tumor necrosis factor‐α inhibitor golimumab: Results of a 24‐Month prospective observation study (GO‐COX Study)

Agafonova

Timokhina

et al. 2023

Int J of Rheum Dis

View full text Add to dashboard Cite

Aim:The hip joint is the most commonly affected non-axial joint in ankylosing spondylitis (AS). Data on the effects of tumor necrosis factorα inhibitors (TNFi) in AS patients with coxitis are limited. The aim of this study was evaluation of coxitis treated with the TNFi golimumab in real-world settings.Methods: This study was a prospective non-interventional cohort study. A total of 39 patients newly prescribed with golimumab were enrolled and followed for up to 24 months. The data collected included BASFI, BASMI, ASDAS-CRP, BASDAI indices. BASRI-hip X-ray score was assessed at baseline, and at 12 and 24 months. Magnetic resonance imaging (MRI) and ultrasound examination data were obtained at baseline, and at 6 and 12 months.Results: Significant improvements in BASFI, BASMI, ASDAS-CRP, BASDAI scores were observed (P ≤ 0.0001), but the BASRI-hip score remained stable. After 6 months of treatment, MRI signs of joint effusion were found in a smaller percentage of patients compared with baseline (P = 0.005 for the right and P = 0.015 for the left hip joints). After 12 months, this percentage was significantly lower than at baseline for the right hip joint (P = 0.005) and numerically lower for the left hip joint (P = 0.098).Ultrasound showed a significant increase in the percentage of patients without inflammatory changes after 6 and 12 months compared with baseline (right hip joint: P = 0.026 and P = 0.045, respectively; left hip joint: P = 0.026 for both time points). Conclusion:Golimumab therapy in AS patients with coxitis was accompanied by improvement in clinical scores, and in MRI and ultrasound findings without obvious radiographic progress.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The hip joint is the most frequently affected non‐axial joint in AS patients 2 . It has been reported that the hip joint is involved in 24%‐54% of AS cases 3–5 .…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Improvement of clinical and radiological manifestations of coxitis in patients with ankylosing spondylitis treated with tumor necrosis factor‐α inhibitor golimumab: Results of a 24‐Month prospective observation study (GO‐COX Study)

Agafonova

Timokhina

et al. 2023

Int J of Rheum Dis

View full text Add to dashboard Cite

show abstract

“…В настоящее время динамика прогрессирования структурных изменений позвоночника при АС в «естественных» условиях и на фоне терапии ГИБП с использованием ингибиторов фактора некроза опухоли α (иФНОα) и ингибиторов интерлейкина 17 активно изучается. Вместе с тем систематические исследования высокой доказательной силы (рандомизированные исследования, метанализы), посвященные прогрессированию структурных изменений ТБС на фоне применения ГИБП, отсутствуют [8].…”

unclassified

The use of biologic therapy in patients with ankylosing spondylitis and coxitis: dynamics of clinical and laboratory parameters and structural progression

Erdes,

Achikyan,

Agafonova

2024

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Hip joint inflammation (coxitis) occurs in almost half of patients with ankylosing spondylitis (AS) and often leads to early disability. A therapy for this condition has not yet been developed, although it is one of the indications for the initiation of biologic therapy in national recommendations. The review presents data from recent clinical trials on the use of biologics, focusing on the Russian national multicenter study of GO-COX in patients with AS with coxitis.Tumour necrosis factor-α inhibitors have been shown to be effective against inflammatory affection of the hip joint in patients with AS, and their administration over a two-year period inhibits the progression of coxitis.

show abstract

An update on the management of axial spondyloarthritis for sports medicine professionals

Danve,

Magrey,

Deodhar

2024

BMC Sports Sci Med Rehabil

View full text Add to dashboard Cite

Background Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which mainly affects the spine and sacroiliac joints, causing longstanding back pain, stiffness, and limited mobility. AxSpA is an underrecognized disease in non-rheumatology practices because of its heterogeneous clinical features that may be difficult to identify. Main body Sports medicine practitioners are well positioned to suspect and recognize axSpA among their patients with chronic back pain and refer them to a rheumatologist. Early referral to a rheumatologist is important for timely diagnosis, prompt treatment, and improved long-term outcomes for patients with axSpA. Physical therapy and nonsteroidal anti-inflammatory drugs (NSAIDs) remain the first-line treatment for and the cornerstone of axSpA management. For patients with inadequate response to or intolerance of NSAIDs, biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic (ts) DMARDs are indicated. These drugs can reduce pain, inflammation, fatigue, and disability and can improve health-related quality of life. The goal of this review is to improve awareness of axSpA among sports medicine practitioners and other non-rheumatologists so that these providers ensure timely referral of patients with suspected axSpA to rheumatologists for appropriate treatment and better outcomes. We also provide an update on current treatment possibilities for axSpA and describe how rheumatologists use treatment guidelines and disease activity measures to identify and optimally treat patients with active axSpA. Conclusion Sports medicine practitioners have an excellent opportunity to identify patients with suspected axSpA and refer them to rheumatologists in a timely manner, as well as monitor symptoms among patients diagnosed with axSpA to identify inadequately controlled disease.

show abstract

Coxitis in axial spondyloarthritis: the unmeasured, yet functionally most important, radiographic progression

Cited by 3 publications

References 21 publications

Improvement of clinical and radiological manifestations of coxitis in patients with ankylosing spondylitis treated with tumor necrosis factor‐α inhibitor golimumab: Results of a 24‐Month prospective observation study (GO‐COX Study)

Improvement of clinical and radiological manifestations of coxitis in patients with ankylosing spondylitis treated with tumor necrosis factor‐α inhibitor golimumab: Results of a 24‐Month prospective observation study (GO‐COX Study)

The use of biologic therapy in patients with ankylosing spondylitis and coxitis: dynamics of clinical and laboratory parameters and structural progression

An update on the management of axial spondyloarthritis for sports medicine professionals

Contact Info

Product

Resources

About